2011
A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck
Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck. Cancer 2011, 117: 3374-3382. PMID: 21246525, PMCID: PMC3135694, DOI: 10.1002/cncr.25852.Peer-Reviewed Original ResearchConceptsAdenoid cystic carcinomaStable diseaseEvaluable patientsObjective responseCystic carcinomaEastern Cooperative Oncology Group performance status 0Day 1Common distant metastatic siteGrade 3 sensory neuropathyMedian progression-free survivalMetastatic adenoid cystic carcinomaGrade 3 anorexiaPerformance status 0Phase 2 trialProgression-free survivalTime of progressionSingle-agent bortezomibCombination of bortezomibDistant metastatic sitesAddition of doxorubicinMeasurable diseaseStatus 0Disease stabilizationFrequent toxicitiesPrior therapy
2007
Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer
Burtness B, Thomas L, Sipples R, McGurk M, Salikooti S, Christoforou M, Mirto G, Salem R, Sosa J, Kloss R, Rahman Z, Chung G, Lacy J, Murren JR. Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer. The Cancer Journal 2007, 13: 257-262. PMID: 17762761, DOI: 10.1097/ppo.0b013e31813c1174.Peer-Reviewed Original ResearchConceptsAdvanced pancreatic cancerPancreatic cancerEligible patientsIrinotecan combinationPartial responseComplete responseEastern Cooperative Oncology Group performance status 0Principal grade 3/4 toxicitiesWorld Health Organization criteriaSafety of docetaxelGrade 3/4 toxicitiesObjective response ratePerformance status 0One-year survivalPhase II trialCombination of docetaxelNormal bilirubin levelsEvaluable patientsFebrile neutropeniaMeasurable diseaseStatus 0Toxic deathsUnresectable diseaseII trialRecurrent disease